<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Annals of Clinical and Experimental Neurology</journal-id><journal-title-group><journal-title xml:lang="en">Annals of Clinical and Experimental Neurology</journal-title><trans-title-group xml:lang="ru"><trans-title>Анналы клинической и экспериментальной неврологии</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2075-5473</issn><issn publication-format="electronic">2409-2533</issn><publisher><publisher-name xml:lang="en">Eco-Vector</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">222</article-id><article-id pub-id-type="doi">10.17816/psaic222</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Original articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Оригинальные статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Unknown</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Experience of using MRI morphometry in Huntington’s disease</article-title><trans-title-group xml:lang="ru"><trans-title>Опыт применения МРТ-морфометрии при болезни Гентингтона</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Yudina</surname><given-names>E. N.</given-names></name><name xml:lang="ru"><surname>Юдина</surname><given-names>Е. Н.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>snillario@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5539-245X</contrib-id><name-alternatives><name xml:lang="en"><surname>Konovalov</surname><given-names>Rodion N.</given-names></name><name xml:lang="ru"><surname>Коновалов</surname><given-names>Родион Николаевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Cand. Sci. (Med.), senior researcher, Neuroradiology department</p></bio><bio xml:lang="ru"><p>к.м.н., с.н.с. отд. лучевой диагностики</p></bio><email>snillario@gmail.com</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Abramycheva</surname><given-names>Natal’ya Yu.</given-names></name><name xml:lang="ru"><surname>Абрамычева</surname><given-names>Наталья Юрьевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>snillario@gmail.com</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Klyushnikov</surname><given-names>Sergey A.</given-names></name><name xml:lang="ru"><surname>Клюшников</surname><given-names>Сергей Анатольевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>snillario@gmail.com</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2704-6282</contrib-id><name-alternatives><name xml:lang="en"><surname>Illarioshkin</surname><given-names>Sergey N.</given-names></name><name xml:lang="ru"><surname>Иллариошкин</surname><given-names>Сергей Николаевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>D. Sci. (Med.), Prof., Corr. Member of the Russian Academy of Sciences, Deputy Director, Head, Department for brain research</p></bio><bio xml:lang="ru"><p>д.м.н., проф., член-корр. РАН, зам. директора по научной работе, рук. отдела исследований мозга</p></bio><email>snillario@gmail.com</email><xref ref-type="aff" rid="aff2"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Research Center of Neurology,</institution></aff><aff><institution xml:lang="ru">ФГБНУ «Научный центр неврологии»</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Research Center of Neurology</institution></aff><aff><institution xml:lang="ru">ФГБНУ «Научный центр неврологии»</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2013-12-09" publication-format="electronic"><day>09</day><month>12</month><year>2013</year></pub-date><volume>7</volume><issue>4</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>16</fpage><lpage>19</lpage><history><date date-type="received" iso-8601-date="2017-02-02"><day>02</day><month>02</month><year>2017</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2013, Yudina E.N., Konovalov R.N., Abramycheva N.Y., Klyushnikov S.A., Illarioshkin S.N.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2013, Yudina E.N., Konovalov R.N., Abramycheva N.Y., Klyushnikov S.A., Illarioshkin S.N.</copyright-statement><copyright-year>2013</copyright-year><copyright-holder xml:lang="en">Yudina E.N., Konovalov R.N., Abramycheva N.Y., Klyushnikov S.A., Illarioshkin S.N.</copyright-holder><copyright-holder xml:lang="ru">Yudina E.N., Konovalov R.N., Abramycheva N.Y., Klyushnikov S.A., Illarioshkin S.N.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://annaly-nevrologii.com/pathID/article/view/222">https://annaly-nevrologii.com/pathID/article/view/222</self-uri><abstract xml:lang="en"><p>One of the most important inherited neurodegenerative disorders, Huntington’s disease (HD), is characterized by cerebral atrophy, the features of which need to be clarified. MRI morphometry allows assessing quantitatively the atrophy of different brain regions, and this method may be regarded as a potential biomarker of neurodegeneration. We used whole-brain voxel-based morphometry (VBM) and region-of-interest (ROI) morphometry in 24 patients with HD, 10 preclinical HD gene carriers and 9 controls. On whole-brain VBM patients had significantly lower grey matter in the caudate, the putamen, and the pre- and postcentral gyri bilaterally compared to controls, while on ROI morphometry the grey matter volume decrease in patients was seen in the caudate, the putamen and the pallidum bilaterally. In clinically unaffected gene carriers the pallidum, the putamen, and the pre-and postcentral gyri bilaterally were larger and the left pallidum was smaller compared to controls. We found more pronounced atrophy of a dominant hemisphere in patients and gene carriers, as well as negative correlation between basal ganglia and cortical structures volumes and the mutation severity, motor and cognitive impairment.</p></abstract><trans-abstract xml:lang="ru"><p>Для одного из наиболее значимых наследственных нейродегенеративных заболеваний – болезни Гентингтона (БГ) – характерна церебральная атрофия, характер которой нуждается в уточнении. Технология МРТ-морфометрии позволяет количественно оценить атрофию различных областей головного мозга, что позволяет рассматривать его как потенциальный биомаркер нейродегенерации. Мы применили у 24 пациентов с БГ, 10 доклинических носителей мутации и 9 здоровых лиц две разновидности метода МРТ-морфометрии – сравнение мозговых объемов в целом и подсчет объемов заранее заданных областей интереса. При сравнении мозговых объемов в целом у пациентов с БГ хвостатое ядро и скорлупа с двух сторон, преи постцентральная извилины были достоверно меньше, чем у лиц из группы контроля, в то время как при сравнении заданных регионов интереса уменьшение объема у больных затронуло хвостатое ядро, бледный шар и скорлупу с двух сторон. У клинически здоровых носителей мутантного гена бледный шар, скорлупа, пре- и постцентральная извилины билатерально оказались достоверно больше, чем у пациентов, а бледный шар слева – меньше, чем в контроле. Выявлены большее поражение доминантной стороны у пациентов и у носителей гена БГ, а также отрицательные корреляции объемов подкорковых и корковых структур с тяжестью мутации, двигательными и когнитивными нарушениями.</p></trans-abstract><kwd-group xml:lang="en"><kwd>MRI morphometry</kwd><kwd>Huntigton’s disease</kwd><kwd>neurodegeneration</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>МРТ-морфометрия</kwd><kwd>болезнь Гентингтона</kwd><kwd>нейродегенерация</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Колесниченко Ю.А, Машин В.В., Иллариошкин С.Н., Зайц Р.Дж. Воксел-ориентированная морфометрия: новый метод оценки локальных вторичных атрофических изменений головного мозга. Анн. клин. эксперимент. неврол. 2007; 4: 35–42.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Aylward E., Mills J., Liu D. et al. Association between age and striatal volume stratified by CAG repeat length in prodromal Huntington disease. PLOS Currents Huntington Dis. 2011; 11.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Draganski B., Bhatia K.P. Brain structure in movement disorders: a neuroimaging perspective. Cur. Opin. Neurol. 2010; 23: 413–419.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Henley S., Ridgway G.R., Scahill R.I. et al. Pitfalls in the use of voxelbased morphometry as a biomarker: examples from Huntington disease. Am. J. Neuroradiol. 2010; 31: 711–719.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Henley S., Wild E., Hobbs N. et al. Relationship between CAG repeat length and brain volume in premanifest and early Huntigton’s disease. J. Neurol. 2009; 256: 203–212.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Ille R., Schäfer A., Scharmüller W. et al. Emotion recognition and experience in Huntington disease: a voxel-based morphometry study. J. Psychiatry Neurosci. 2011; 36: 6–10.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Kassubek J., Pinkhardt E.H., Dietmaier A. et al. Fully automated atlas-based MR imaging volumetry in Huntington disease, compared with manual volumetry. Am. J. Neuroradiol. 2011; 32: 1328–1332.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Kassubek J., Juengling F.D., Kioschies T. et al. Topography of cerebral atrophy in early Huntington’s disease: a voxel based morphometric MRI study. J. Neurol. Neurosurg. Psychiatry 2004; 75: 213–220.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Klöppel S., Chu C., Tan G.C. et al. Automatic detection of preclinical neurodegeneration. Neurology 2009; 72: 426–431.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Lambrecqa V., Langboura N., Guehla D. et al. Evolution of brain gray matter loss in Huntington’s disease: a meta-analysis. Eur. J. Neurol. 2013; 20: 315–321.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Muhlau M., Gaser C., Wohlschager A. et al. Striatal atrophy in Huntington’s disease is leftward biased. In: World Congress on Huntington’s disease. Dresden, 2007: 120.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Rosas H.D., Salat D.H., Lee S. et al. Complexity and heterogeneity: what drives the ever changing brain in Huntigton’s disease? Ann. NY Acad. Sci. 2008; 1147: 196.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Stoffers D., Sheldon S., Kuperman J.M. et al. Contrasting gray and white matter changes in preclinical Huntington disease. Neurology 2010; 74: 1208–1216.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Tabrizi S.J., Langbehn D.R., Leavitt B.R. et al. TRACK-HD investigators. Biological and clinical manifestations of Huntington’s disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. Lancet Neurol. 2009; 8: 791–801.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Tabrizi S.J., Reilmann R., Roos R.A. et al. Potential endpoints for clinical trials in premanifest and early Huntington’s disease in the TRACK-HD study: analysis of 24 month observational data. Lancet Neurol. 2012; 11: 42–53.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Tabrizi S.J., Scahill R.I., Durr A. et al. Biological and clinical changes in premanifest and early stage Huntington’s disease in the TRACK-HD study: the 12-month longitudinal analysis. Lancet Neurol. 2011; 10: 31–42.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Whitwell J.L., Josephs K.A. Voxel-based morphometry and its application to movement disorders. Parkinsonism Relat. Disord. 2007; 13: 406–416.</mixed-citation></ref></ref-list></back></article>
